Source:http://linkedlifedata.com/resource/pubmed/id/10875473
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2000-10-27
|
pubmed:abstractText |
The aim of this study was to assess the relationship between the prevalence of GB virus C/hepatitis G virus (GBV-C/HGV) RNA and that of antibody to the putative E2 protein (anti-E2) in hemodialysis patients. GBV-C/HGV RNA in serum was detected by a reverse transcription polymerase chain reaction (RT-PCR) assay, and anti-E2 was measured in 244 hemodialysis patients by enzyme-linked immunosorbent assay using recombinant E2 protein. The GBV-C/HGV RNA level was determined by competitive RT-PCR with an interval of 1 year. GBV-C/HGV RNA, anti-E2. and both together were detected in 11 (4.5%), in 19 (7.8%), and in 3 patients (1.2%), respectively. Comparison of clinical characteristics between GBV-C/HGV RNA-positive patients and negative patients revealed the longer duration of hemodialysis (9.8 years vs. 6.0 years; p < 0.05), and the greater frequency of anti-hepatitis C virus (HCV) (63.6% vs. 20.3%; p < 0.05) and HCV RNA (36.4% vs. 12.9%; p < 0.05) in GBV-C/HGV RNA-positive patients. The GBV-C/HGV RNA levels of patients who were positive for anti-E2 remained under detection limit (< 10(2) copies/mL), whereas only one of eight patients who were negative for anti-E2 showed a GBV-C/HGV RNA level under detection limit (p < 0.05). The presence of anti-E2 in serum was associated with loss of detectable GBV-C/HGV RNA or with a very small amount of HCV RNA in hemodialysis patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Envelope Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/glycoprotein E2, GB virus C
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0192-0790
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
425-8
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10875473-Antibodies, Viral,
pubmed-meshheading:10875473-Antigens, Viral,
pubmed-meshheading:10875473-Cohort Studies,
pubmed-meshheading:10875473-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:10875473-Female,
pubmed-meshheading:10875473-Flaviviridae,
pubmed-meshheading:10875473-Hepatitis, Viral, Human,
pubmed-meshheading:10875473-Humans,
pubmed-meshheading:10875473-Male,
pubmed-meshheading:10875473-Middle Aged,
pubmed-meshheading:10875473-RNA, Viral,
pubmed-meshheading:10875473-Renal Dialysis,
pubmed-meshheading:10875473-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:10875473-Viral Envelope Proteins,
pubmed-meshheading:10875473-Viremia
|
pubmed:year |
2000
|
pubmed:articleTitle |
GB virus C/hepatitis G viremia and antibody response to the E2 protein of hepatitis G virus in hemodialysis patients.
|
pubmed:affiliation |
First Department of Internal Medicine, Yamaguchi University, School of Medicine, Ube, Japan.
|
pubmed:publicationType |
Journal Article
|